SEC Form 4 · accession 0000899243-18-004892
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jung Choi
Officer — See Remarks
Period of report
Feb 16, 2018
Accepted (ET)
Feb 21, 2018 · 6:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 16, 2018 | S | 1,600 | $62.95 | D | 140,877 | D | |
| Common Stock | Feb 16, 2018 | M | 198 | $3.40 | A | 141,075 | D | |
| Common Stock | Feb 16, 2018 | M | 601 | $3.40 | A | 141,676 | D | |
| Common Stock | Feb 16, 2018 | M | 601 | $3.40 | A | 142,277 | D | |
| Common Stock | Feb 16, 2018 | S | 1,400 | $62.95 | D | 140,877 | D | |
| Common Stock | holding | — | — | — | 25,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $3.40 | Feb 16, 2018 | M | 198 | D | — | Apr 8, 2025 | Common Stock | 198 | 75,558 | D |
| Stock Option (Right to Buy)F4 | $3.40 | Feb 16, 2018 | M | 601 | D | — | Apr 8, 2025 | Common Stock | 601 | 4,478 | D |
| Stock Option (Right to Buy)F5 | $3.40 | Feb 16, 2018 | M | 601 | D | — | Apr 8, 2025 | Common Stock | 601 | 4,478 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter.
- F325% of the shares subject to this option vested and became exercisable on April 6, 2016 and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter.
- F4On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.
- F5On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.
Remarks
Chief Business and Strategy Officer